LRMR 8-K: SEC filing
Larimar Therapeutics
Filed with the SEC on · accession 0001193125-26-462054
LRMR filed a 8-K (current report) with the SEC on Nov 16, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Summary of the filing
Larimar Therapeutics announced its financial results and operational highlights for the third quarter ended September 30, 2026, via a press release furnished as Exhibit 99.1 to its Form 8-K.
Key details
✦ Ask GOAX AI about this filing — what it means for LRMR, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for LRMR?
Click hereFrequently asked questions
What did LRMR file with the SEC on Nov 16, 2026?
LRMR filed a 8-K (SEC filing). Larimar Therapeutics announced its financial results and operational highlights for the third quarter ended September 30, 2026, via a press release furnished as Exhibit 99.1 to its Form 8-K.
How do I read a 8-K?
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Other LRMR SEC filings
Get alerts when LRMR files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days